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Abstract Non-tuberculous mycobacterial (NTM) infections are increasingly rapidly worldwide.
The reason for this phenomenon is unclear, but may include the ageing population, the
increasing use of immunosuppressive drugs, the increasing prevalence of diseases that confer
susceptibility to NTM, such as COPD and bronchiectasis, and growing testing for NTM. Aware-
ness of the NTM related diseases is rising but is still suboptimal. Guidelines from the American
Thoracic Society and Infectious Diseases Society of America have provided a framework for eval-
uating disease and evaluating care. Compliance with these guidelines is, however, very poor
globally.
NTM infections are amongst the most challenging cases that respiratory and infectious
diseases physicians face. The challenges include intrinsic antibiotic resistance, complex
drug regimens, poor tolerability and signiﬁcant side effects associated with therapy and
poor response rates. The decision to initiate treatment is therefore often difﬁcult
and requires careful evaluation of beneﬁts and risks. Optimal management of NTM infections
requires multidisciplinary care with close collaboration between physicians, microbiologists,
physiotherapist/allied health professionals, primary care physicians and the patient.
There remains a need for greater research into the epidemiology, clinical evaluation and
treatment of NTM pulmonary disease. Randomised clinical trials are now being conducted which
may provide useful data on the effectiveness of some new and existing therapies.
In this review, we discuss the growing importance of NTM pulmonary disease and the oppor-
tunities for progress in clinical research for these conditions.sa de Pneumologia. Published by Elsevier Espan˜a, S.L.U. This is an
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-© 2018 Sociedade Portugue
open access article under t
nc-nd/4.0/).∗ Corresponding author.
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As previously noted, NTM are present in the environmentNon-tuberculous mycobacterial pulmonary infections
Introduction
Nontuberculous mycobacterial pulmonary disease (NTM-PD),
also referred to variously as NTM-pulmonary disease or
NTM-lung disease is caused by infection with a range of
pathogenic species of NTM.1--3 These diseases are rela-
tively rare but place a major burden on patients and their
physicians because they are complex to manage, requiring
prolonged antibiotic regimens with a great deal of com-
plexity in the microbiology, radiology, drug treatments,
drug--drug interactions and other aspects of treatment.1,2
With these factors combined, NTM patients are among the
most complex and challenging cases that pulmonologists
face in clinical practice. NTM are also responsible for non-
pulmonary disease and disseminated disease. These forms
of the disease will not be discussed here.
The incidence and prevalence of these infections is ris-
ing alongside increases in the prevalence of predisposing
diseases like chronic obstructive pulmonary disease (COPD)
and bronchiectasis, and the increasing life expectancy of
patients with cystic ﬁbrosis.4--9 All pulmonary physicians
need to know to suspect NTM pulmonary disease, how to
recognise and diagnose it and to understand the priniciples
of treatment.
In this concise review, we discuss the clinical aspects of
NTM pulmonary disease with a focus on diagnosis and ther-
apy.
Epidemiology
More than a hundred NTM species have been described
and the number is growing (www.bacterio.cict.fr/m/
mycobacterium.html). Fortunately most of them have no
clinical signiﬁcance and relatively few are responsible for
lung disease. NTM are ubiquitous in the environment and are
readily identiﬁed in community and household water sources
amongst other habitats.1 As a result, humans are constantly
being exposed to NTM, but NTM-PD remains uncommon
because only a small proportion of individuals appear to be
susceptible.10--13 It is remarkable that in the past decade,
data have been published from Europe, North America, Aus-
tralia and Asia all reporting a consistent increase in the
incidence and prevalence of NTM-PD.14--20 The extent to
which this increase is real, or reﬂects increased testing
and reporting is unclear. Unlike TB, NTM infection is not a
reportable disease in the majority of countries which limits
the quality and reliability of data collection.
Regional differences in the prevalence of NTM disease
have been demonstrated around the world including 9.8
per 100,000 from Canada in 2010,14 8.6 per 100,000 from
Oregon, USA15 or less than 1 in 100,000 from Brazil.16 NTM
isolation appears to be highly prevalent in Asia by contrast
with one study suggesting a national prevalence in Japan
of between 33 and 65 per 100,000, predominantly due to
Mycobacterium avium complex (MAC).17 Although estimates
closer to those reported in Canada and US were found in a
study from Taiwan.18In Europe, a recent study from the UK identiﬁed a rising
incidence of NTM isolation driven almost exclusively by an
increase in MAC disease with incidence rising from 5.6 per
100,000 to 7.6 per 100,000 over the period 2007--2012.21
a
t
p121
ingshausen et al. reported a prevalence of 2.3 per 100,000
or NTM pulmonary disease in 2009 in Germany rising to 3.3
er 100,000 in 2014.22
Thus internationally the rates of NTM disease are there-
ore relatively similar, allowing for differences in the
ethods of reporting, the deﬁnition of cases and the dif-
erent methods employed in the studies.
A large observational study in Europe identiﬁed impor-
ant genographic variation in the species isolated from
atietns with MAC being most frequent in Northern Europe
accounting for 44% of all NTM isolates vs 31% in South-
rn Europe) and a predominance of Mycobacterium xenopi
n Southern Europe (accounting for 21% of NTM isolates in
outhern Europe vs 6% in Nothern Europe).23
Thus NTM-PD remains a rare disease, but one of increas-
ng importance. It is a problem worldwide and although the
istribution of different species varies according to geo-
raphical location, MAC is the predominant species in nearly
ll studies.14--23
linical characteristics
TM-PD is typically chronic, slowly progressive and dif-
cult to diagnose. It can present at any age, but is
ost common in patients older than 50.24--27 NTM-PD
s strongly associated with conditions that compromise
ulmonary or systemic immunity such as bronchiectasis,
OPD, cystic ﬁbrosis or other chronic respiratory disorders
nd systemic immunodeﬁciency.28--34 The disease is often
ubclassiﬁed into nodular-bronchiectatic and ﬁbrocavitary
‘phenotypes’’. Although there is a high degree of overlap
etween these subtypes, they are clinically useful.24--27 In
urope and the USA the nodular-bronchiectatic phenotype
atients are typically elderly causasian females while ﬁbro-
avitary disease is strongly associated with co-morbid COPD
nd is therefore more common in men.27
A distinct ‘‘morphotype’’ of individuals with nodular-
ronchiectatic NTM-PD has been reported in the United
tates consisting of post-menopausal females with tall
tature, low body mass index, scoliosis, pectus excava-
um, mitral valve prolapse and middle lobe and lingula
ronchiectasis. Post menopausal females often with mid-
le and lingula nodular bronchiectactic NTM disease are
eferred to as ‘‘Lady Windermere syndrome’’.35,36 A MAC-
ssociated hypersensitivity pneumonitis-like illness has also
een reported to occur following exposure to aerosolized
AC mainly in indoor hot tubs and is referred to as hot tub
ung.7
The symptoms of NTM-PD are non-speciﬁc. Diagnosis is
ften delayed because symptoms may appear to be part of
he underlying disorder, or may be misdiagnosed. Patients
ost frequently have cough, sputum productions, breath-
essness, profound fatigue, weight loss and fever.
iagnosisnd particularly in environmental water sources. They may
herefore contaminate sputum specimens or be transiently
resent in the airways without causing disease leading to
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‘false positive’’ sputum samples. Therefore Isolation of an
TM species in clinical samples is frequently not associated
ith clinically signiﬁcant disease.37 Critieria for diagno-
is ﬁrst proposed in the 2007 American Thoracic Society
uidelines remain the standard used internationally.27 These
equire clinical, microbiological and radiological evidence of
isease before the diagnosis can be conﬁrmed. Speciﬁcally,
wo isolates of NTM from a non-sterile site (typically sputum)
r a single bronchoalveolar lavage or lung biopsy specimen,
ymptoms attributable to NTM-PD and radiological evidence
f NTM-PD are considered sufﬁcient evidence for a diagnosis
f NTM-PD (Table 1).
It is recommended that 2--3 early morning sputum sam-
les on different days are used for diagnosis of NTM-PD.1,27
n patients with a high index of suspicion where spontaneous
putum has not been obtained it is appropriate to use spu-
um induction or bronchoscopy. The least invasive procedure
hat can achieve a deﬁnitive diagnosis is preferred.1 Once
he sample is obtained it is stained for the presence of acid-
ast bacilli, most frequently with Ziehl--Neelsen stain. This
oes not discriminate between Mycobacterium tuberculosis
nd NTM. The broad availability now of nucleic acid ampliﬁ-
ation (NAA) tests for MTB such as the Xpert MTB/RIF assay,
owever, allows a better distinction of species in the early
hase of disease: a negative NAA gives a strong early indi-
ator that a sample positive for AFB on stain is likely to
ontain an NTM.1,27,38,39 Culture remains the gold standard
or diagnosis and is used for subsequent conﬁrmation of the
resence of NTM, species identiﬁcation and drug suscepti-
ility testing.
Table 1 IDSA/ATS criteria for diagnosis of NTM- pulmonary
disease.1,27
Clinical features
Pulmonary symptoms attributable to NTM disease.
Radiology
Nodular or cavitary opacities on chest radiograph, or a
high-resolution CT scan that shows multifocal
bronchiectasis with multiple small nodules.
Appropriate exclusion of other diagnoses.
Microbiology
Positive culture results from at least two separate
expectorated sputum samples; if the results are
non-diagnostic, consider repeat sputum AFB smears and
cultures.
or
Positive culture results from at least one bronchial wash
or lavage.
or
Transbronchial or other lung biopsy with mycobacterial
histopathological features (granulomatous inﬂammation or
AFB) and positive culture for NTM or biopsy showing
mycobacterial histopathological features (granulomatous
inﬂammation or AFB) and one or more sputum or bronchial
washings that are culture-positive for NTM.
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echanisms of disease
TM is an area of signiﬁcant activity in terms of understand-
ng basic mechanisms of disease. The outcome of pulmonary
TM disease is likely to reﬂect a complex interplay between
he exposure (e.g. the infecting dose of NTM, the num-
er of organisms and duration of exposure), the organism
virulence and pathogenicity) and the host (immune sta-
us, genetic risk factors, underlying chronic lung disease)
Fig. 1).40--44 To date, there is limited information to under-
tand this complex interaction.
Some organisms are more pathogenic than others and are
herefore more likely to cause clinically relevant disease.
Among the host risk factors, the impact of chronic lung
isease is discussed below. Immunosuppression is a key
isk factor, and during the early days of the HIV epidemic
ost literature regarding NTM concerned disseminated MAC
nfection as a manifestation of the acquired immunodeﬁ-
iency syndrome.45 This is now exceptionally rare in the
ra of highly active anti-retroviral therapy. NTM infection
s now more frequently encountered in the context of
atrogenic immunosuppression with drugs directed against
umour necrosis factor alpha or its receptor, corticosteroids
r other systemic immunsuppressive drugs.46--48 Recent data
uggests that inhaled corticosteroids (ICS) in COPD patients
and perhaps to a lesser extent asthma patients) increase
he risk of NTM.49--51 A Danish case control study found ICS
ncreased the risk of NTM by 29× among COPD patients, with
igh dose ICS increasing the risk to nearly 50×.49 Brode and
olleagues recently extended these ﬁndings in a large popu-
ation based study among 417,494 patients with obstructive
ung disease. They found ICS increased the risk of NTM by
6%, with ﬂuticasone containing drugs increasing the risk by
ore than double.51 This increases the evidence that ICS
s associated with infectious complications in patients with
OPD.52--55 The IL-12/interferon gamma pathway is thought
o be critical to host defence against mycobacteria and
nherited defects in this pathway are associated with NTM-
D and disseminated NTM.56 The extent to which apparently
poradic NTM is associated with defects in this pathway is
ot fully known.
Some of the ﬁrst data from whole exome sequencing
tudies among NTM patients have been reported, includ-
ng a novel susceptibility gene on chromosome 6 identiﬁed
s the TTK protein kinase gene involved in mitosis and
NA repair.57--59 Another exome sequencing study impli-
ated cystic ﬁbrosis transmembrane conductance regulator
CFTR) and cilia related genes in the pathogenesis of NTM.59
atsuyama et al. recently described the transcriptional
esponse of the primary respiratory epithelial cell cultures
o MAC and Mycobacterium abscessus infection. They found
ownregulation of genes involved in ciliary function, sup-
orting a vicious cycle concept of NTM infection, and found
. abscessus tended to be more pro-inﬂammatory than
AC.60 Microbiological research is also ongoing. NTM have
lassically been considered an intracellular pathogen but
vist showed in CF than M. abscessus can grow in bioﬁlms.61
ngoing research in this area is likely to add signiﬁcantly to
ur understanding of the pathogenesis of NTM infections.
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Although the exact route of NTM acquisition has not
been well established, considering the broad distribution of
NTM in the environment it is very likely that the organisms
are ingested, inhaled or implanted. Aerosolization of small
droplets is the probably cause of pulmonary disease. Unlike
TB, person to person transmission has not been convincingly
identiﬁed for the majority of NTM. Person to person trans-
mission of M. abscessus has been identiﬁed among patients
with cystic ﬁbrosis.41,62
NTM and underlying diseases
NTM can be associated with virually any structural lung dis-
ease but is most frequently described in the context of COPD
and bronchiectasis.63--66 Pneumoconioses such as silicosis are
also strongly linked to NTM infection, although the preva-
lence of such diseases is rapidly falling worldiwde.63,64 A
meta-analysis of observational studies suggests that 9% of
bronchiectasis patients are infected with NTM.67 This sum-
mary statistics hides enourmous heterogeneity and includes
rates varying from 0% to 60%.66--71 Henkle et al. reported
on patient characteristics and treatment of bronchiecta-
sis in the US bronchiectasis registry. Among 1247 patients
with NTM, 83% were female, 19% had co-existing COPD, 22%
were infected with Pseudomonas aeruginosa. ICS therapy
was used by 36%.71 Patients are frequently infected with
other organisms such as P. aeruginosa and there is also a
link between NTM infection and Aspergillus disease, includ-
ing invasive Aspergillosis.72--75 Among the large number of
aetiologies associated with bronchiectasis, cystic ﬁbrosis is
the most commonly associated with NTM infection.76 NTM
infections are increasing among CF populations worldwide.
The reasons for this are unclear but this may reﬂect the
increasing lifespan of patients and the greater success that
has been achieved in controlling traditional bacterial infec-
tions like P. aeruginosa, as well as greater awareness leading
to increased NTM diagnosis.77--79 Current estimates are that
NTM infects between 4% and 32% of CF patients.76
There is also increasing interest in the frequent iso-
lation of NTM in patients with previous or current M.
tuberculosis infection. Other respiratory diseases commonly
linked to NTM include pulmonary alveolar proteinosis, where
autoantibodies against GM-CSF may impair host macrophage
responses to NTM leading to infection particularly with
MAC.80--83
s
t
se development of NTM pulmonary disease.
adiology
s noted for the clinical presentation, the radiological
ppearances of NTM-PD are varied and non-speciﬁc. There
re two major radiological patterns of disease, notably ﬁbro-
avitary and nodular bronchiectatic disease, although it is
oted that featues of both can overlap.24 The ﬁbrocavitary
orm of the disease overlaps radiologically, and sometimes
linically, with the appearances of pulmonary TB. This dis-
ase is therefore often associated with cavities and areas of
pacity located in the upper lobes, which may be associated
ith volume loss, pleural thickening and bronchiectasis. The
avities are most frequently described as ‘‘thin-walled’’ and
ther features of pulmonary TB are likely to be absent.27
In nodular-bronchiectatic disease (Fig. 2) there is
ronchial dilatation most frequently affecting the mid-
le lobe and lingula, often associated with nodules and
ree-in-bud opacities.1,27 There may be other features
uch as consolidation, and the severity of the radiological
ronchiectasis may vary from cylindrical to cystic. Since
TM is thought to be both a cause and a complication
f bronchiectasis it should be noted that any radiological
ppearance of bronchiectasis may be potentially associated
ith NTM. An example of ﬁbrocavitary disease is shown in
ig. 3.
herapy
n every patient, the decision to treat NTM-PD is potentially
hallenging and involves balancing the beneﬁts of treatment
nd the risks of drug toxicity.27,84 The ideal scenario is that
atients with NTM-PD are managed in experienced centres
y physicians and multidisciplinary teams who manage large
umbers of NTM patients and have access to the microbio-
ogical facilities and antibiotic susceptibility data required
o make the most informed decisions.84 This likely to be the
ase for only a tiny minority of patients worldwide.
NTM-PD is usually a slowly progressive disorder and so
he urgency to initiate treatment is not the same as in the
ase of pulmonary TB, unless the patients is immunocom-
romised or has invasive disease. Patients may be observed
ithout treatment to determine whether disease is progres-
ive radiologically or clinically.1,27
The goal of treatment is to improve the patients symp-
oms and their long term quality of life. This is an important
tatement, as there objective of NTM lung disease treatment
124 J.D. Chalmers et al.
Figure 2 Nodular-bronchiectatic phenotypes of NTM. The CT images (left to right) show severe bronchiectasis in the Lingula in a
patient with M. avium lung disease. Tree-in-bud is most easily visible in the right lung and the middle image shows this more clearly
in the same patient. The right image shows a bilateral nodular bronchiectatic disease in a gentleman with M. abscessus infected.
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n the CT scan. In the left upper lobe there is a thick walled ca
s often described in textbooks and review articles as being
o render the sputum negative by culture for NTM for 12
onths which is important and the deﬁnition of microbiolog-
cal response. Nevertheless, the initial discussion regarding
hether to initiate treatment should take into account what
he patient wishes to achieve with therapy, and not only a
iscussion of microbiological considerations.85--87
It is also essential to manage the patients underly-
ng diseases such as COPD and bronchiectasis and careful
ontrol of other airway infections, including P. aerugin-
sa infection.88--90 Attention to airway clearance to control
putum and related symptoms, and prevention of respi-
atory infections through vaccination are as important as
reatment of the NTM.88--90 In patients with bronchiectasis,
ttention should be paid to identifying any underlying cause
nd to treating this where appropriate.91 In patients with
mmunosuppression such as HIV or use of immunosuppress-
ve drugs, the immunodeﬁciency should be reversed as far
s possible.
Therapy is continued for at least 12 months after culture
onverts to negative (culture conversion).1,27 Prolonged regi-
ens are required because relapse is common. A recent pilot
tudy showed that typical NTM regimens lack early bacteri-
cidal activity in vivo, i.e. they fail to achieve reductions
f bacterial load over the initial months of treatment. Pro-
onged therapy is therefore required to achieve cure.92AC therapy
he treatment of MAC lung disease is typically with combi-
ation therapy incorporating a macrolide (clarithromycin or
i
n
i
cisease. The patient has COPD and severe emphysema is evident
Sputum samples were persistently positive for M. avium.
zithromycin).1,27 The standard regimen includes a rifamycin
rifampicin or rifabutin), ethambutol and a macrolide.
atients will receive therapy for 18--24 months until spu-
um is negative by culture for 12 months or more. Patients
ithout cavitary disease may expect the get a similar
ate of microbiological cure with less cost and toxicity by
aking three times per week therapy as demonstrated in
ecent observational cohort studies.93 No difference has
een found between clarithomycin and azithromycin con-
aining regimes.94
Fibrocavitary/cavitary disease is treated with daily
herapy with recent guidelines also advocating the use
f amikacin or streptomycin for 2--3 months in severe
isease.1,27
The treatment of macrolide resistant or treatment
efractory MAC lung disease is particularly challenging.
lternative therapies used include moxiﬂoxacin, aminogly-
osides, inhaled amikacin and clofazimine. Seeking expert
dvice in the management of these patients is strongly advo-
ated.
ycobacterium kansasii
ompared to MAC or M. abscessus complex (MABC), M.
ansasii may be regarded as a readily treatable pathogen. It
s usually sensitive to standard anti-TB drugs expect pyrazi-
amide. The recommend drug regimen is rifampicin 600mg,
soniazid 300mg and ethambutol 15mg/kg. Treatment is
ontinued for 12 months after sputum conversion.
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Table 2 Antibiotic treatment suggestions. Deﬁnition of severe disease includes AFB smear positivity, cavitation, severe symp-
toms or evidence of systemic illness. Clarithromycin 1 g daily is administered in at least two divided doses, e.g. 500mg twice
daily. All therapies are continued until sputum is culture negative for at least 12 months.1,27
Organism/severity Antibiotic regimen
Non-severe MAC-PD Rifampicin 600mg+ ethambutol 25mg/kg + azithromycin 500mg or clarithromycin 1 g
per day, three times per week.
Severe MAC-PD Rifampicin 600mg+ ethambutol 15mg/kg + azithromycin 250mg or clarithromycin 1 g
daily. Consider intravenous or nebulised amikacin.
Clarithromycin resistant MAC-PD Rifampicin 600mg daily, ethambutol 15mg/kg and isoniazid 300mg (+pyridoxine
10mg daily) or moxiﬂoxacin 400mg daily. Consider IV or nebulised amikacin.
M. kansasii (rifampicin sensitive) Rifampicin 600mg+ ethambutol 15mg/kg + isoniazid 300mg (+pyridoxine 10mg daily)
or azithromycin 250mg daily or clarithromycin 1 g daily.
M. malmoense Rifampicin 600mg+ ethambutol 15mg/kg + azithromycin 250mg or clarithromycin 1 g
daily. Consider amikacin IV or nebulised in the case of severe disease.
M. xenopi Rifampicin 600mg+ ethambutol 15mg/kg + azithromycin 250mg or clarithromycin
1 g +moxiﬂoxacin 400mg daily or isoniazid 300mg (+pyridoxine 10mg) daily. Consider
amikacin IV or nebulised in severe disease
M. abscessus (macrolide sensitive or
inducible macrolide resistance)
Initial phase: At least 4 week initial phase of intravenous amikacin, tigecycline,
imipenem and oral clarithromycin or oral azithromycin.
Continuation phase: nebulised amikacin + oral macrolide in combination with 1--3
drugs selected based on drug susceptibility and tolerance (clofazimine, linezolid,
minocycline/doxycycline, moxiﬂoxacin/ciproﬂoxacin and co-trimoxazole.
M. abscessus (macrolide resistant) Initial phase: At least 4 week initial phase of intravenous amikacin, tigecycline and
imipenem.
Continuation phase: nebulised amikacin in combination with 2--4 drugs selected
based on drug susceptibility and tolerance (clofazimine, linezolid,
minocycline/doxycycline, moxiﬂoxacin/ciproﬂoxacin and co-trimoxazole.
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This is more challenging and the therapy is typically indi-
vidualised based on the results of drug susceptibility tests,
potential drug--drug interactions and tolerability.1,27 Current
guideline recommendations are shown in Table 2. Macrolide
based therapy is recommended but data suggests it is more
effective against Mycobacterium massiliense compared to
M. abscessus due to the effect of inducible macrolide
resistance.95 The overall success rate of therapy is low and
therefore surgical resection should be carefully considered
when the disease is localised sufﬁciently for this to be an
option.
The taxomony of MABC has evolved in recent years with
the identiﬁcation of subspecies by whole genome sequenc-
ing MABC is now subdivied into at least 3 subspecies --
M. abscessus subspecies abscessus, M. abscessus subsp.
massiliense and M. abscessus subsp. bolletii.95--100 Along-
side the revision of the classiﬁcation of M. abscessus,
the identiﬁcation of inducible macrolide resistance has
been an important development.97--100 M. abscessus con-
tains an erm gene encoding for a methyltransferase that
methylates the site of action of macrolides within the 23s
rRNA. As a result, the organism may appear suspcetible to
macrolides early (i.e. at day 3) but is resistant after pro-
longed incubation (day 14).97--100 There is variation in erm
function between subspecies of the abscessus genus, specif-
ically M. bolletii and abscessus typically possess erm gene
n
w
m
iequences associated with inducible macrolide resistance
hile the erm gene is dysfuncton in M. massiliense leading
o macrolide susceptibility.97--100
mportant issues with NTM therapy
ompliance with long term treaments in all conditions is
ften low. In the case of NTM lung disease where treatments
an be toxic and where immediate symptomatic beneﬁts
re not always obvious, encouraging adherence can be a
ajor challenge.101 Gastrointestinal side effects are the
ost common issue, particularly with macrolides. Hepatox-
city is common with rifampicin, macrolides, impenem and
igecycline among others. Aminoglycosides cause renal tox-
city and hearing impairment. Patients should be warned
o report tinnitus, hearing loss of vestibular symptoms,
ot only if using aminoglycosides but also macrolides.1,27
eripheral neuropathy is an important adverse effect of
inezolid and ethambutol. Visual acuity should be tested in
atients receiving ethambutol.1,27 Rifampicin induces liver
nzymes leading to enhanced metabolism of many drugs
including macrolides and ﬂuoroquinolones, but also many
ther drugs such as oral contraceptives, with the result
hat woman of child bearing potential should use alter-
ative contraception). The medications used by patients
ith NTM-PD should be carefully reviewed prior to com-
encing therapy with a view to identifying potential drug
nteractions.1,27
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ntibiotic susceptibility testing
hether antibiotic susceptibility testing is helpful to guide
TM therapy is controversial.1,27 There are clear discrepen-
ies between in vitro resistance and in vivo response for
number of antibiotics with the exception of macrolides
nd amikacin.102 For M. avium complex pulmonary disease
clear link between macrolide and amikacin resistance
nd clinical outcomes has been shown.102 Similarly for M.
ansasii lung disease rifampicin susceptibility predicts clin-
cal response.103,104 Thus MAC isolates should be tested for
esistance to clarithromcyin and M. kansasii isolates should
e tested for resistance to rifampicin and clarithromycin.
solates resistant to rifampicin may be tested against sec-
ndary agents such as rifabutin, ethambutol, isoniazid,
uoroquinolones and amikacin.1,27
For the rapidly growing Mycobacteria such as M. absces-
us complex susceptibility testing is typically performed
or amikacin, cefoxitin, ﬂuoroquinolones, macrolides,
etracyclines, imipenem, linezolid, trimethoprim-
ulfamethoxazole and aminoglycosides. Prolonged
ncubation to 14 days is used to identify inducible macrolide
esistance.27
ew antimicrobial agents for NTM lung disease
mikacin is active against the majority of NTM species
uy systemic administraation of amikacin is associated
ith typical aminoglycoside toxicities such as oto and
ephrotoxicity.105 The development of inhaled amikacin for
efractory NTM lung disease may therefore represent a sig-
iﬁcant advance.106 Data supporting the use of nebulised
mikacin are from retrospective cohort studies, but ran-
omised controlled trials have recently completed using
iposomal amikacin. In the phase 2 study in which 44
atients received inhaled amikacin and 45 received placebo
n addition to a multidrug regimen for 84 days, the primary
ndpoint of change in semi-quantiative NTM culture was not
et (p = 0.072) but there was an increase in sputum clear-
nce of NTM which is a more clinically relevant end-point
32% vs 9%, p = 0.006).107
Linezolid has been recently repurposed from the treat-
ent of Staphylococcal skin and soft tissue infections to the
reatment of MDR-TB and also has activitiy against some NTM
pecies.108--110 The long term safety is a major limitation as
he drug is associated with peripheral neuropathy, haema-
ological toxicity and other adverse effects.108 Winthrop
nd colleagues recently described a series of 102 patients
ith NTM-PD treated with linezolid. 45% developed adverse
ffects, with peripheral neuropathy being most common
24%), along with gastrointestinal upset (9%), anaemia (8%)
nd thrombocytopenia (6%). 87% of those developing adverse
ffects had to stop therapy.108 Tigecycline similarly has good
n vitro activity against MABC but its use is limitated due to
ausea/vomiing and other side effects.111
Clofaziimine has activity against MDR-TB infections and
as recently been proposed as a potential drug in NTM
nfections.112--114 It is administered orally, can be well tol-
rated in MDR-TB and is active against both slow growing
nd rapid growing NTMs. Bedaquiline is another oral drug
sed successfully in the treatment of MDR-TB which has
w
p
a
tJ.D. Chalmers et al.
een reported in small series to be successfully used as
salvage therapy.115--118 Major concerns including QT pro-
ongation have been reported although recent data in TB
uggest this concern may be less severe than previously
hought.118
TM disease in real-life
dherence to clinical guidelines for pulmonary NTM is sub-
ptimal to say the least. A recent multinational survey
n the EU and Japan which included 1429 NTM-PD cases
ound remarkable divergence from practice guidelines. Only
6.9% of MAC-PD patients received the recommended regi-
en of rifampicin/ethambutol and a macrolide for greater
han 6 months.119 There was also large variation in guide-
ine compliance rates between countries. This suggests an
rgent need to educate physicians about evidence-based
TM treatment and to raise awareness of the disease.
urgery
he poor response rates of standard chemotherapy for most
TM-PD cases means that surgery should be considered in
ny case where it is feasible.1,27,120 This is particularly the
ase in patients with refractory disease or where extensive
rug resistance is a problem. Surgery may take the form of
omplete resection of localised disease, or debulking of an
rea of severe disease which is thought to be driving the
ajority of symptoms.1,27 The other major indication for
urgery is massive haemoptysis that cannot be controlled
ith medical therapy or bronchial artery embolisation.
ase series show microbiological responses of 80--100% with
urgery for NTM but post-operative complications are a sig-
iﬁcant problem with a post-operative mortality rate of up
o 3%.120--122 Surgical management is best delivered by a mul-
idisciplinary team incorporating physicians and surgeons
xperienced in the management of NTM-PD.
rognosis
failure to achieve a microbiological response by 6 monhs of
ppropriate antimicrobial therapy and a failure to achieve
putum culture conversion after 12 months of appropriate
herapy have been suggested as deﬁnitions of treatment
ailure or refractory NTM disease.1,27 Overall treatment suc-
ess rates vary markedly in the literature, from 13% to
6% for MAC disease for example.26 A recent meta-analysis
f 16 studies including 1462 patients receiving macrolide
ased regimens found a sustained culture conversion rate of
0%.123
Prognosis is related to the initial severity of disease,
o the initial therapy receiving and to the clinical phe-
otype. Koh et al. recently described the outcomes of a
arge series of 481 patients with MAC-PD who received >12
onths of antibiotic treatment. Patients without cavitation
ere more likely to have a favourable outcome (88%) com-
ared to those with ﬁbrocavitary (76%) or a mix of cavitary
nd bronchiectatic disease (78%). This study emphasised
he importance of re-infection in this patient population as
Non-tuberculous mycobacterial pulmonary infections
29% were re-infected or relapsed following treatment, with
genotyping showing 74% of cases were due to reinfection.24
Research priorities
A recent USA based project identiﬁed a series of patient
centred research priorities for NTM, including topics around
transmission, diagnosis such as achiving more rapid diag-
nosis and developing algorithms to identify patients at
risk.124 Other recommendations included better microbio-
logical techniques that are more sensitive, and improved
treatment options. Among the treatment recommenda-
tions were improved treatment for anxiety and depression,
improved non-pharmacological treatments such as exercise
and airway clearance and improved methods including pos-
sibly algorithms or prediction tools to identify patients who
will require antibiotic treatment. The authors also recom-
mended the development of a severity assessment algorithm
similar to that already available in bronchiectasis, and the
identiﬁcation of biomarkers.124--127 For antibiotic therapy,
there is a need to identify superior antibiotics, improved
methods of delivering antibiotics, repurposed non-antibiotic
drugs that may enhance mycobacterial clearance and regi-
mens that can be given for a shorter duration.
This list may make it seem that no aspect of NTM dis-
ease has been fully optimised, and this is true. Nevertheless,
substantial progress has been made in recent years in under-
standing the burden of disease, optimising diagnosis and
implementing appropriate treatment.
The next 10 years will hopefully see breakthroughs in
these areas that will start to make a major impact on the
burden of NTM-PD
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